血小板-淋巴细胞比值与系统性红斑狼疮疾病活动度的相关性研究

doi:10.3969/j.issn.1006-6233.2022.05.08

Abstract
Figure/Table
References
Related Citation (7)

Download: PDF (1297 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective: To explore the correlation between platelet to lymphocyte ratio (PLR) and disease activity in patients with systemic lupus erythematosus(SLE)during the first episode and initial treatment. Methods: A total of 572 patients with first attack and initial treatment of SLE were enrolled as SLE group, and 572 healthy people during the same period were enrolled as healthy control group, according to SLE disease activity index 2000, SLE patients were divided into low activity group (SLEDAI ≤ 9 points, n=294) and high activity group (SLEDAI > 9 points, n=278), the PLR of the above groups were compared respectively, and spearman statistical analysis was performed to investigate the correlation between PLR and disease activity of SLE. Results: The PLR of SLE patients was significantly higher than that of healthy controls (P<0.05). In SLE patients, the PLR of the high activity group was significantly higher than that of the low activity group (P<0.05). PLR was positively correlated with SLEDAI score (r=0.291, P<0.05), Erythrocyte sedimentation rate(r=0.207, P<0.05), C-reactive protein (r=0.302, P<0.05), anti-ds-DNA antibody(r=0.098, P<0.05),24h urine protein (r=0.173, P<0.05), negatively correlated with complement C3(r=-0.257, P<0.05) and complement C4(r=-0.223, P<0.05). The area under the receiver operating characteristic curve of PLR for predicting the high activity of SLE is 0.639 (P<0.05). When the optimal critical value was 170, the sensitivity was 58.3% and the specificity was 65.6%. Conclusion: PLR can be used as one of the evaluation indicators for disease activity of SLE.

Key words： Platelet to lymphocyte ratio Systemic lupus erythematosus Erythrocyte sedimentation rate

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors

Cite this article:

URL:

http://www.hbyxzzs.cn/EN/10.3969/j.issn.1006-6233.2022.05.08 OR http://www.hbyxzzs.cn/EN/Y2022/V28/I5/740

[1] 吴文英,陶东红,张如峰,等.来氟米特治疗系统性红斑狼疮的临床疗效及对血清BAFF MCP-4 IL-8 IL-10水平的影响[J].河北医学,2018,24(12):1957~1960.
[2] Hepburn A L,Narat S,Mason J C.The management of peripheral blood cytopenias in systemic lupus erythematosus[J].Rheumatology,2010,49(12):2243~2254.
[3] Yildiz F,Gokmen O.Haematologic indices and disease activity index in primary sjogren's syndrome[J].International Journal of Clinical Practice,2021,75(3):e13992.
[4] Sargin G,Senturk T,Yavasoglu I,et al.Relationship between neutrophil-lymphocyte,platelet-lymphocyte ratio and disease activity in rheumatoid arthritis treated with rituximab[J].International Journal of Rheumatic Diseases,2018,21(12):2122~2127.
[5] Moulton VR,Suarez-Fueyo A,Meidan E,et al.Pathogenesis of human systemic lupus erythematosus:a cellular perspective[J].Trends in molecular medicine,2017,23(7):615~635.
[6] Martin M,Guffroy A,Argemi X,et al.Lupus erythemateux systemique et lymphopénie:aspects cliniques et physiopathologiques[J].La Revue de Medecine Interne,2017,38(9):603~613.
[7] 严姗姗,张育.血小板对风湿性疾病发病机制的影响[J].血栓与止血学,2014,20(2):84~87.
[8] Scherlinger M,Guillotin V,Truchetet ME,et al.Systemic lupus erythematosus and systemic sclerosis:all roads lead to platelets[J].Autoimmunity Reviews,2018,17(6):625~635.
[9] Linge P,Fortin P R,Lood C,et al.The non-haemostatic role of platelets in systemic lupus erythematosus[J].Nature Reviews Rheumatology,2018,14(4):195~213.
[10] Jung J H,Soh M S,Ahn Y H,et al.Thrombocytopenia in systemic lupus erythematosus:clinical manifestations,treatment,and prognosis in 230 patients[J].Medicine,2016,95(6):e2818.
[11] 李敏,夏育民.系统性红斑狼疮男性患者临床特征研究进展[J].中国麻风皮肤病杂志,2022,38(3):5.
[12] Soliman WM,Sherif NM,Ghanima IM,et al.Neutrophil to lymphocyte and platelet to lymphocyte ratios in systemic lupus erythematosus:relation with disease activity and lupus nephritis[J].Reumatologia Clinica,2020,16(4):255~261.